Women's Heart Disease: Why Sex-Specific Differences Lead to Underdiagnosis and Higher Mortality

Why Do Women Present Differently with Heart Disease?

The traditional understanding of heart attack presentation, centered on sudden, crushing chest pain radiating to the left arm, was largely derived from studies conducted predominantly in men. While chest pain or pressure remains the most common symptom in both sexes, women are significantly more likely to present with atypical symptoms. A landmark study published in Circulation analyzing over 500,000 heart attack patients found that women were 42% more likely than men to present without chest pain. Common atypical presentations in women include unusual fatigue (occurring in up to 70% of female MI patients in some studies), shortness of breath, nausea or vomiting, back or jaw pain, dizziness, and indigestion-like symptoms.

These differences in presentation have tangible consequences. Research published in the European Heart Journal found that women experiencing a heart attack wait an average of 37% longer than men to seek emergency care, partly because they do not recognize their symptoms as cardiac in origin. Once in the emergency department, women face additional diagnostic delays, with a study in the British Medical Journal showing that women with STEMI (ST-elevation myocardial infarction) experienced longer door-to-balloon times for percutaneous coronary intervention. Women are also less likely to receive guideline-directed therapies including aspirin, beta-blockers, statins, and cardiac catheterization.

The underlying pathophysiology also differs between sexes. While men more commonly develop obstructive coronary artery disease (large vessel atherosclerosis), women are more likely to have coronary microvascular disease (MVD), in which the small arteries of the heart are affected. Standard diagnostic tools like coronary angiography may appear normal in women with MVD, leading to false reassurance. Newer diagnostic techniques, including coronary flow reserve testing and cardiac MRI with adenosine stress, are better at detecting microvascular disease and are increasingly recommended when standard evaluation is negative but clinical suspicion remains high.

What Are SCAD and Takotsubo Cardiomyopathy?

Spontaneous coronary artery dissection (SCAD) is a condition in which the wall of a coronary artery tears spontaneously, creating a false lumen that can obstruct blood flow and cause a heart attack. Unlike atherosclerotic heart disease, SCAD typically occurs in young to middle-aged women without traditional cardiovascular risk factors. Approximately 90% of SCAD cases occur in women, with a mean age at presentation of 44-53 years. SCAD is now recognized as the most common cause of heart attack in women under 50, accounting for an estimated 25-35% of cases in this demographic. Associations include fibromuscular dysplasia (found in 25-80% of SCAD patients), peripartum status, connective tissue disorders, and extreme physical or emotional stress.

Takotsubo cardiomyopathy, also known as stress cardiomyopathy or broken heart syndrome, is a condition in which intense emotional or physical stress triggers sudden, temporary weakening of the heart muscle, mimicking a heart attack. The condition was first described in Japan in 1990 and named for the takotsubo (octopus trap), which the affected left ventricle resembles on imaging due to apical ballooning. Approximately 90% of cases occur in postmenopausal women, with a mean age of 65-70 years. The International Takotsubo Registry, published in the New England Journal of Medicine, found that emotional triggers (grief, fear, anger) were identified in 27.7% of cases, physical triggers (acute illness, surgery) in 36%, and no identifiable trigger in 28.5%.

Both conditions require awareness among clinicians for timely diagnosis. SCAD is typically diagnosed on coronary angiography, though intravascular imaging (optical coherence tomography or intravascular ultrasound) is often needed for confirmation. Management differs significantly from atherosclerotic heart attacks: conservative treatment is preferred for SCAD, as stenting can propagate the dissection, and most patients recover with medical management alone. Takotsubo is diagnosed by characteristic wall motion abnormalities on echocardiography or cardiac MRI in the absence of significant coronary artery disease, and typically resolves within days to weeks with supportive care, though complications including cardiogenic shock occur in approximately 10% of cases.

How Do Pregnancy Complications Predict Future Heart Disease in Women?

Pregnancy has been described as a natural cardiovascular stress test, and complications during pregnancy can unmask underlying vascular vulnerability that predicts future heart disease risk. The American Heart Association formally recognized adverse pregnancy outcomes as cardiovascular risk enhancers in its 2019 guidelines, and the AHA's 2021 scientific statement on cardiovascular disease in women specifically calls for incorporating pregnancy history into cardiovascular risk assessment. This represents a paradigm shift in how clinicians evaluate heart disease risk in women.

Preeclampsia, a hypertensive disorder affecting 5-8% of pregnancies, is the most extensively studied pregnancy complication in relation to future cardiovascular risk. A meta-analysis published in the BMJ, encompassing over 3 million women, found that women with a history of preeclampsia had a 2.16-fold increased risk of ischemic heart disease, a 1.81-fold increased risk of stroke, and a 4-fold increased risk of chronic hypertension. Gestational diabetes, which affects 6-9% of pregnancies, confers a 7-fold increased risk of developing type 2 diabetes and a 2-fold increased risk of cardiovascular events later in life. Preterm delivery (before 37 weeks) has been associated with a 1.4-2.0-fold increased risk of ischemic heart disease.

The AHA's Go Red for Women campaign, launched in 2004, has been instrumental in raising awareness that heart disease is the leading killer of women, responsible for approximately 1 in 3 female deaths globally. Since the campaign's inception, cardiovascular mortality in women has declined by approximately 30% in the United States, partly attributable to increased awareness, improved screening, and better adherence to evidence-based treatments. However, disparities persist, with Black women experiencing a 2-3 times higher pregnancy-related mortality rate and a disproportionate burden of cardiovascular disease. Integrating pregnancy history into routine cardiovascular risk assessment, implementing postpartum cardiovascular screening programs, and addressing racial disparities remain critical priorities for reducing heart disease deaths in women.